TAVVE® STUDY: The TrAnscatheter Venous Valve Endoprosthesis
TAVVE Pivotal Clinical Trial
Prospective, Randomized, Multi-Center Trial with No Open Surgical Safety Concerns and Measuring Both Hemodynamic Improvement and Clinical Benefit
The TAVVE Study is a planned multicenter pivotal clinical trial evaluating the safety and effectiveness of the enVVe® System in patients with severe Deep Venous Insufficiency (DVI). The study builds on the clinical foundation established by our surgical replacement venous valve and will assess the safety and effeteness of our next-generation, non-surgical replacement venous valve.
Primary Efficacy Endpoints
Change in regurgitant volume in the target vein zone at 12 months compared to treatment and control arms, core lab adjudicated
Clinical Improvement (rVCSS)
Primary Safety Endpoints
Composite of all cause death and device related events at 30 days
Key Milestones*
– Site Activation: Q2 2026
– Commence Enrollment: Q3 2026
– Early Data Readout from Initial Patients: Q4 2026
– Full Enrollment: 2028
– Pivotal Data: 2029
* Stated milestones are based on Management’s current expectations and are subject to change
Working with Prestigious Clinical Sites Across the United States
